SUBJECTS : Breast Cancer | | Prevention | Diagnosis | Treatment | Breast Cancer Surger
LATEST MANUSCRIPTS IN Breast
- Min Seo Choi, Jee Suk Chang, Kyubo Kim, Jin Hee Kim, Tae Hyung Kim, Sungmin Kim, Hyejung Cha, Oyeon Cho, Jin Hwa Choi, Myungsoo Kim, Juree Kim, Tae Gyu Kim, Seung-Gu Yeo, Ah Ram Chang, Sung-Ja Ahn, Jinhyun Choi, Ki Mun Kang, Jeanny Kwon, Taeryool Koo, Mi Young Kim, Seo Hee Choi, Bae Kwon Jeong, Bum-Sup Jang, In Young Jo, Hyebin Lee, Nalee Kim, Hae Jin Park, Jung Ho Im, Sea-Won Lee, Yeona Cho, Sun Young Lee, Ji Hyun Chang, Jaehee Chun, Eung Man Lee, Jin Sung Kim, Kyung Hwan Shin, Yong Bae Kim. Assessment of deep learning-based auto-contouring on interobserver consistency in target volume and organs-at-risk delineation for breast cancer: Implications for RTQA program in a multi-institutional study. Breast (Edinburgh, Scotland). 2023, 73: 103599
Cited : 0Read More - T Blackmore, K Norman, V Burrett, J Scarlet, I Campbell, R Lawrenson. Key factors in the decision-making process for mastectomy alone or breast reconstruction: A qualitative analysis. Breast (Edinburgh, Scotland). 2023, 73: 103600Cited : 2Read More
- Matteo Ghilli, Andrea Vittorio Emanuele Lisa, Marzia Salgarello, Giovanni Papa, Mario Rietjens, Secondo Folli, Annalisa Curcio, Guglielmo Ferrari, Francesco Caruso, Vittorio Altomare, Daniele Friedman, Maria Carmen De Santis, Fiorenza De Rose, Bruno Meduri, Francesca De Felice, Lorenza Marino, Francesca Cucciarelli, Stefania Montemezzi, Pietro Panizza, Paolo Belli, Francesca Caumo, Valeriano Vinci, Giorgio De Santis, Marco Klinger, Manuela Roncella, . Oncoplastic and reconstructive surgery in SENONETWORK Italian breast centers: lights and shadows. Breast (Edinburgh, Scotland). 2023, 73: 103601Cited : 0Read More
- Pavla Ticha, Andrej Sukop. Patient-reported outcomes in bilateral prophylactic mastectomy with breast reconstruction: A narrative review. Breast (Edinburgh, Scotland). 2023, 73: 103602Cited : 2Read More
- Yanyu Zhang, Xiaoxi Huang, Xingxing Yu, Wei He, Kamila Czene, Haomin Yang. Hematological and biochemical markers influencing breast cancer risk and mortality: Prospective cohort study in the UK Biobank by multi-state models. Breast (Edinburgh, Scotland). 2023, 73: 103603Cited : 1Read More
- Masahiro Ito, Masakazu Amari, Akiko Sato, Masahiro Hikichi, Aru Sakamoto, Asumi Yamazaki, Shigehira Saji. Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy. Breast (Edinburgh, Scotland). 2023, 73: 103604Cited : 0Read More
- Maartje A C Schreurs, Teresa Ramón Y Cajal, Muriel A Adank, J Margriet Collée, Antoinette Hollestelle, Jeroen van Rooij, Marjanka K Schmidt, Maartje J Hooning. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. Breast (Edinburgh, Scotland). 2023, 73: 103611Cited : 1Read More
- Kelvin Kh Bao, Jeffrey Ch Chan, Jocelyn G Chan, Leone Sutanto, Ka Man Cheung, Harry Hy Yiu. Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Breast (Edinburgh, Scotland). 2023, 73: 103612Cited : 0Read More
- Sandrine Hild, Delphine Teigné, Damien Fairier, Yannick Ruelle, Isabelle Aubin-Auger, Stéphanie Sidorkiewicz, Marie Citrini, Xavier Gocko, Catherine Cerisey, Emilie Ferrat, Cédric Rat. Development and evaluation of a decision aid for women eligible for organized breast cancer screening according to international standards: A multi-method study. Breast (Edinburgh, Scotland). 2023, 73: 103613Cited : 0Read More
- Emma Söderberg, Fredrik Wärnberg, Anna-Karin Wennstig, Greger Nilsson, Hans Garmo, Lars Holmberg, Carl Blomqvist, Malin Sund, Charlotta Wadsten. Association of clinicopathologic variables and patient preference with the choice of surgical treatment for early-stage breast cancer: A registry-based study. Breast (Edinburgh, Scotland). 2023, 73: 103614Cited : 0Read More
- Anja Tüchler, Antoine De Pauw, Corinna Ernst, Amélie Anota, Inge M M Lakeman, Julia Dick, Nienke van der Stoep, Christi J van Asperen, Monika Maringa, Natalie Herold, Britta Blümcke, Robert Remy, Anke Westerhoff, Denise J Stommel-Jenner, Eléonore Frouin, Lisa Richters, Lisa Golmard, Nadine Kütting, Chrystelle Colas, Barbara Wappenschmidt, Kerstin Rhiem, Peter Devilee, Dominique Stoppa-Lyonnet, Rita K Schmutzler, Eric Hahnen. Clinical implications of incorporating genetic and non-genetic risk factors in CanRisk-based breast cancer risk prediction. Breast (Edinburgh, Scotland). 2023, 73: 103615Cited : 1Read More
- Irina Palimaru Manhoobi, Trine Tramm, Søren Redsted, Anne Bodilsen, Leslie Foldager, Peer Christiansen. Digital breast tomosynthesis versus X-ray of the breast specimen for intraoperative margin assessment: A randomized trial. Breast (Edinburgh, Scotland). 2023, 73: 103616Cited : 0Read More
- Mathias Schwartz, Sabrina Ibadioune, Sophie Vacher, Marie-Charlotte Villy, Olfa Trabelsi-Grati, Jessica Le Gall, Sandrine M Caputo, Hélène Delhomelle, Mathilde Warcoin, Virginie Moncoutier, Christine Bourneix, Nadia Boutry-Kryza, Antoine De Pauw, Marc-Henri Stern, Bruno Buecher, Emmanuelle Mouret-Fourme, Chrystelle Colas, Dominique Stoppa-Lyonnet, Julien Masliah-Planchon, Lisa Golmard, Ivan Bieche. Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement. Breast (Edinburgh, Scotland). 2023, 73: 103620Cited : 0Read More
- Kadri Altundag. Is there a link between elevated C-reactive protein levels and specific breast cancer molecular subtypes? Breast (Edinburgh, Scotland). 2023, 73: 103621Cited : 0Read More
- Thomas Decker, Kerstin Lüdtke-Heckenkamp, Luidmila Melnichuk, Nader Hirmas, Kristina Lübbe, Mark-Oliver Zahn, Marcus Schmidt, Carsten Denkert, Ralf Lorenz, Volkmar Müller, Dirk-Michael Zahm, Christoph Mundhenke, Stefan Bauer, Marc Thill, Peter Seropian, Natalie Filmann, Sibylle Loibl. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA). Breast (Edinburgh, Scotland). 2023, 72: 103575Cited : 3Read More
